Accelerate Diagnostics

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company's revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the Accelerate ID/AST System development pipeline, the company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Company Growth (employees)
Type
Public
HQ
Tucson, US
Founded
2004
Size (employees)
193 (est)
Accelerate Diagnostics was founded in 2004 and is headquartered in Tucson, US

Accelerate Diagnostics Office Locations

Accelerate Diagnostics has offices in Tucson, Castelldefels
Tucson, US
Castelldefels, ES

Accelerate Diagnostics Metrics

Accelerate Diagnostics Summary

Market capitalization

$1.2 b

Closing share price

$23.3
Accelerate Diagnostics's current market capitalization is $1.2 b.

Accelerate Diagnostics Financials

Accelerate Diagnostics's revenue is $246 k in FY, 2016 which is a 67.3% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$48.3 k$122 k$147 k$246 k

Revenue growth, %

152.7%20.5%67.3%

EBIT

($15.3 m)($31.5 m)($45.5 m)

Net Income

($15.3 m)($30.9 m)($45.5 m)($66.4 m)

Operating cash flow

$18 m$23.5 m$67 m

Accelerate Diagnostics Market Value History

Accelerate Diagnostics Online Presence

Accelerate Diagnostics News

Accelerate Diagnostics Company Life

You may also be interested in